Comparison · NCT04598477-ba4c1c0f
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin. Trial comparisons, record NCT04598477-ba4c1c0f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04598477-ba4c1c0f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.545 | 0.448 | 0.638 | wilson | |
| Risk in group 2 | 0.542 | 0.403 | 0.674 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00289 | -0.161 | 0.17 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.733 | 1.38 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.508 | 2.02 | log | |
| Number needed to treat, for one more participant with the outcome on Efgartigimod-efgartigimod PH20 SC than on Placebo-efgartigimod PH20 SC | 346 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Efgartigimod-efgartigimod PH20 SC | Participants who received efgartigimod PH20 SC in antecedent study ARGX-113-1904 | 55 | 101 | OG000 |
| Group 2 | Placebo-efgartigimod PH20 SC | Participants who received placebo PH20 SC in antecedent study ARGX-113-1904. | 26 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin
- Description
- CRmin defined as the absence of new lesions and complete healing of established lesions while the participant was receiving prednisone at ≤10 mg/day for at least 8 weeks.
- Time frame
- Up to 60 weeks
- Population
- Safety set
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- NCT number
- NCT04598477
- Phases
- PHASE3
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus
- Interventions
- efgartigimod PH20 SC, prednisone
- Lead sponsor
- argenx
- Results first posted
- 2025-03-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04598477?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04598477-ba4c1c0f